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Fibulin-4 deficiency increases 
TGF-β signalling in aortic smooth 
muscle cells due to elevated TGF-
β2 levels
N. W. M. Ramnath1,2,*, L. J. A. C. Hawinkels3,4,*, P. M. van Heijningen1, L. te Riet2,5, 
M. Paauwe3, M. Vermeij6, A. H. J. Danser5, R. Kanaar1,7, P. ten Dijke3 & J. Essers1,2,7
Fibulins are extracellular matrix proteins associated with elastic fibres. Homozygous Fibulin-4 
mutations lead to life-threatening abnormalities such as aortic aneurysms. Aortic aneurysms 
in Fibulin-4 mutant mice were associated with upregulation of TGF-β signalling. How Fibulin-4 
deficiency leads to deregulation of the TGF-β pathway is largely unknown. Isolated aortic smooth 
muscle cells (SMCs) from Fibulin-4 deficient mice showed reduced growth, which could be 
reversed by treatment with TGF-β neutralizing antibodies. In Fibulin-4 deficient SMCs increased 
TGF-β signalling was detected using a transcriptional reporter assay and by increased SMAD2 
phosphorylation. Next, we investigated if the increased activity was due to increased levels of the 
three TGF-β isoforms. These data revealed slightly increased TGF-β1 and markedly increased TGF-
β2 levels. Significantly increased TGF-β2 levels were also detectable in plasma from homozygous 
Fibulin-4R/R mice, not in wild type mice. TGF-β2 levels were reduced after losartan treatment, an 
angiotensin-II type-1 receptor blocker, known to prevent aortic aneurysm formation. In conclusion, 
we have shown increased TGF-β signalling in isolated SMCs from Fibulin-4 deficient mouse aortas, 
not only caused by increased levels of TGF-β1, but especially TGF-β2. These data provide new insights 
in the molecular interaction between Fibulin-4 and TGF-β pathway regulation in the pathogenesis of 
aortic aneurysms.
In developed countries 1–2% of all deaths are caused by aortic aneurysms and dissections1. In these 
countries the incidence of thoracic aortic aneurysms (TAA) is approximately 25 per 100,000 persons per 
year2. In general, a TAA is characterized by degeneration of the extracellular matrix (ECM) and vascular 
smooth muscle cells (SMCs), including (phenotypic) loss of SMCs and changes in SMC proliferation3–5. 
Several genes have been identified in both syndromic and non-syndromic forms of TAA, including ECM 
genes, genes encoding contractile proteins in SMCs and genes involved in the regulation of the trans-
forming growth factor (TGF)-β pathway6–8.
There are three mammalian TGF-β isoforms: TGF-β 1, -β 2 and -β 3. They are encoded by differ-
ent genes, but show a high degree of amino acid sequence homology. All TGF-β isoforms bind to the 
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latency-associated protein (LAP) and via the latent TGF-β binding protein (LTBP) to the ECM. Upon 
activation TGF-β s can bind to the type-II TGF-β receptors (Tβ RII), which recruit the type-I TGF-β 
receptor (Tβ RI), also called activin receptor-like kinase (ALK)-5. ALK-5 is transphosphorylated by 
Tβ RII and subsequently downstream SMAD proteins (i.e. SMAD2/3) are phosphorylated. Activated 
SMAD2 and -3 associate with SMAD4, leading to translocation to the nucleus where they interact with 
target gene promoters and regulate transcription of genes encoding for plasminogen activator inhibitor 
(PAI)-I, matrix metalloproteinases (MMPs) and ECM proteins9.
A crucial role for the TGF-β pathway in syndromes associated with TAA became evident from both 
studies in patients and in mouse models10–14. Although TAAs are usually associated with increased 
TGF-β signalling, this association has also been observed with loss of function mutations in TGF-β and 
TGF-β receptors15. The identification of these mutations has led to new insights in the pathogenesis of 
aneurysm formation, but the molecular mechanism remains to be elucidated.
Mutations in genes of the TGF-β pathway and the ECM lead to phenotypic and functional SMC loss: 
Tgfbr2 mutations in Loeys-Dietz syndrome lead to decreased expression of SMC contractile proteins5. 
Furthermore, SMCs from mice with Marfan syndrome, another syndromic form of TAAs caused by 
mutations in the ECM glycoprotein Fibrillin-1, display an altered expression profile with morphological 
changes, but retain expression of vascular SMC markers4. In addition, increased TGF-β signalling inhib-
its proliferation of SMCs16.
Upregulated TGF-β signalling has been observed in another heritable form of TAA caused by a 
deficiency in the extracellular matrix protein Fibulin-413,17–20. Fibulin-4 regulates proper elastogenesis 
by tethering lysyl oxidase to tropoelastin to facilitate crosslinking21,22. In Fibulin-4 deficient patients 
and mice elevated TGF-β signalling has been shown12,13,20. However, the exact mechanism by which 
Fibulin-4 deficiency leads to increased TGF-β signalling remains to be determined. To further investi-
gate this we isolated SMCs from the aortic arch of hypomorphic Fibulin-4 (Fibulin-4R/R) mice, display-
ing a 4-fold reduction of Fibulin-4 expression. This leads to congenital vascular abnormalities in these 
mice, including TAAs and vascular tortuosity12. Heterozygous Fibulin-4+/R mice, which have a 2-fold 
reduced Fibulin-4 expression, show minor irregularities and ECM changes in the aortic wall. Our data 
reveal that TGF-β signalling is enhanced in isolated SMCs derived from the aortas of Fibulin-4 deficient 
mice. We observed a decreased proliferation rate in Fibulin-4R/R SMCs, which could be reverted by addi-
tion of TGF-β neutralizing antibodies. We found that this increased TGF-β signal transduction activity 
is not only associated with increased levels of TGF-β 1, but especially with enhanced TGF-β 2 levels. 
Increased levels of TGF-β 2 could also be detected in blood and aortic tissue lysates of the Fibulin-4R/R 
mice. Treatment of Fibulin-4R/R mice with losartan, an angiotensin II type-1 receptor blocker, reduced 
the increased TGF-β 2 levels in blood plasma. This study shows that increased TGF-β signalling in SMCs 
of Fibulin-4 deficient mice leads to decreased proliferation of SMCs and could be caused by increased 
bioavailability of TGF-β 1 and especially TGF-β 2.
Results
Characterization of SMCs derived from Fibulin-4 deficient aortas. To examine TGF-β signalling 
in Fibulin-4 deficient SMCs, we isolated SMCs from the aortic arches of Fibulin-4+/+, Fibulin-4+/R and 
Fibulin-4R/R mice. To confirm that the cells we isolated were SMCs, the cells were analysed for the pres-
ence of SMC markers, including α -smooth muscle actin (α -SMA), smooth muscle specific protein-22 
(SM22), smooth muscle myosin heavy chain II (MHC II) and fibroblast specific protein 1 (FSP1), which 
stains SMCs with a rhomboid phenotype23,24. Human umbilical vein endothelial cells (HUVECs) were 
taken along as positive control for CD31 staining and were negative for all other markers, while mouse 
embryonic fibroblasts (MEFs) were positive controls for FSP1, and SMA and SM22 staining25. Isolated 
SMCs showed positive staining for α -SMA, SM22, MHC II, FSP1 and were negative for CD31 (Fig. 1a) 
confirming the SMC phenotype. QPCR expression analysis also showed no detectable CD31 and von 
Willebrand Factor (an additional endothelial marker) mRNA expression (data not shown). α -SMA was 
highly expressed and seemed somewhat increased in Fibulin-4+/R and Fibulin-4R/R SMCs (Fig. 1b). Next, 
the levels of Fibulin-4 were analysed by QPCR. These data revealed that expression levels of Fibulin-4 
mRNA in Fibulin-4+/R and Fibulin-4R/R SMCs were downregulated (Fig.  1c). These data show that we 
isolated a population of SMCs with a gradual reduced Fibulin-4 expression level, which we used for 
further cell biological and molecular analyses.
TGF-β reduces proliferation of Fibulin-4R/R SMCs. Previously we showed in 10 days old Fibulin-4R/R 
mice increased BrdU uptake indicating increased proliferation of SMCs, leading to changes in the tunica 
adventitia of the aorta12. However, in adult Fibulin-4R/R mice (100 days old) increased proliferation was 
observed specifically in the endothelial layer (Fig.  2a). No proliferation of SMCs in the adventitia or 
media of the aortic wall was observed. Next, we analysed proliferation rates of the SMCs with reduced 
Fibulin-4 expression in vitro. Figure  2b shows similar growth rates of all three genotypes until day 5, 
after which proliferation was decreased in Fibulin-4R/R SMCs. As TGF-β can inhibit cell proliferation, 
we determined whether the reduced growth of Fibulin-4R/R SMCs is a consequence of increased TGF-β 
activity. Therefore, SMCs were treated with TGF-β neutralizing antibodies (nAb), which neutralize all 
three TGF-β isoforms26,27. Treatment with the TGF-β nAb reversed the growth inhibition observed in 
Fibulin-4R/R SMCs compared to Fibulin-4+/+ SMCs (Fig.  2c–f). On day 7 the number of Fibulin-4R/R 
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SMCs was significantly increased after treatment with TGF-β nAb compared to non-treated Fibulin-4R/R 
SMCs. Moreover, proliferation was similar to Fibulin-4+/+ SMCs. These data indicate that Fibulin-4 defi-
ciency leads to increased TGF-β , which inhibits proliferation of SMCs.
Fibulin-4 expression regulates TGF-β signalling in aortic SMCs. Since we observed that TGF-β 
neutralizing antibodies revert the decreased proliferation rates of Fibulin-4R/R SMCs, we further ana-
lysed transcriptional consequences of increased TGF-β signalling in these cells using a SMAD3/SMAD4 
dependent promoter transcriptional reporter construct (CAGA-luciferase)28. Although there was a differ-
ence in proliferation between different genotypes at later time points, this was not observed during the 
shorter duration of this assay (Fig. 3a). To determine whether transfection efficiency was similar between 
the different genotypes a green fluorescent protein (GFP) expressing construct was transfected and GFP 
expression determined. Flow cytometric analysis showed no differences between the percentages of GFP 
expressing Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs (Fig. 3b) and thus no differences in transfec-
tion efficiencies among these different genotype. Next, we used the CAGA-luciferase reporter construct 
to assess TGF-β signalling activity in Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs. Stimulation with 
Figure 1. Characterization of isolated SMCs from the aortic arch. (a) Immunofluorescent staining of 
aortic SMCs isolated from Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R mice showed that these cells stained 
positively for SMA, SM22, MHC II and FSP1. The SMCs were negative for the endothelial marker CD31, 
while HUVECs were positive. HUVECs were negative for all other stainings. MEFs stained positive for 
SMA, SM22 and FSP1 and were negative for MHC II and CD31. Magnification 20x, scale bar 100 μ m. 
(b) Fibulin-4+/R and Fibulin-4R/R SMCs show gradual increased SMA mRNA expression levels compared 
to Fibulin-4+/+ SMCs. (c) Fibulin-4 mRNA expression in SMCs. Fibulin-4+/R and Fibulin-4R/R SMCs show 
gradual decreased Fibulin-4 mRNA expression levels compared to Fibulin-4+/+ SMCs.
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TGF-β of Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs showed a strong induction of luciferase activ-
ity, which was increased in a Fibulin-4 dose-dependent manner (Fig. 3c). Addition of the Tβ RI kinase 
inhibitor SB431542, a compound selectively blocking TGF-β type-I receptor kinase activity29, abolished 
TGF-β -induced transcriptional responses. Analysis of downstream pSMAD2 and pSMAD3 by western 
blotting revealed a gradual increase in SMAD2 and SMAD3 phosphorylation after stimulation with 
TGF-β in Fibulin-4+/R and Fibulin-4R/R SMCs compared to Fibulin-4+/+ SMCs (Fig. 3d), confirming the 
CAGA-luciferase reporter data. These data indicate that Fibullin-4 deficient cells show increased signal-
ling upon exogenous TGF-β stimulation.
Figure 2. Reduced proliferation of Fibulin-4R/R SMCs is reversed by inhibition of the TGF-β pathway. 
(a) Increased BrdU uptake indicating active proliferation of endothelial cells is present in the aortic wall 
from 100 days old Fibulin-4R/R mice and is indicated by the arrows. (b) Growth analyses of Fibulin-4+/+, 
Fibulin-4+/R and Fibulin-4R/R SMCs revealed a reduced growth starting from day 5 for Fibulin-4R/R SMCs as 
compared to Fibulin-4+/+ SMCs (3 dishes per experiment were counted and the average of 3 independent 
experiments is shown). Treatment of (c) Fibulin-4+/+, (d) Fibulin-4+/R and (e,f) Fibulin-4R/R SMCs with TGF-
β neutralizing antibodies (nAb) significantly increased proliferation of Fibulin-4R/R SMCs from day 5. (f) At 
day 7 the number of treated Fibulin-4R/R SMCs was significantly higher and comparable to the amount of 
Fibulin-4+/+ SMCs (*p < 0.05, **p < 0.01). Data represent 3 independent experiments performed in triplicate.
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To explore whether basal TGF-β signalling is also affected in Fibulin-4 deficient cells, SMCs were trans-
fected with the CAGA-luciferase reporter and TGF-β signalling without exogenous addition of TGF-β 
ligand was analysed. This showed that luciferase activity was already increased in untreated Fibulin-4R/R 
SMCs compared to Fibulin-4+/+ SMCs (Fig. 3e). This could be reversed by SB431542, suggesting a TGF-β 
mediated effect. Western blot analysis showed gradually increased basal phosphorylation of SMAD2 and 
SMAD3 in untreated Fibulin-4+/R and Fibulin-4R/R SMCs (Fig.  3f). Taken together, these data indicate 
that increased phosphorylation of SMAD2/3 leads to enhanced transcriptional activation of downstream 
TGF- β signalling genes and reduced growth in Fibulin-4 mutant cells.
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Figure 3. Increased TGF-β signalling in Fibulin-4 deficient SMCs. (a) Fibulin-4+/+, Fibulin-4+/R and 
Fibulin-4R/R SMCs show similar proliferation rates in the time course of the experiment (MTS proliferation 
assay) (b) Transfection with green fluorescent protein (GFP) encoding plasmids display no difference in 
percentage of transfected SMCs between Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs. (c) The TGF-β 
response assay reveals a gradual increase in TGF-β activity in Fibulin-4+/R and Fibulin-4R/R SMCs compared 
to Fibulin-4+/+ SMCs, after stimulation with exogenous TGF-β . Data represent fold change relative to 
unstimulated Fibulin-4+/+ SMCs. Addition of the ALK-5 kinase inhibitor (SB431542) abolishes the TGF-β 
response in Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs. (d) Western blot analyses for TGF-β signalling 
downstream mediators pSMAD2 and pSMAD3 on TGF-β stimulated SMCs show a gradual increase in TGF-
β signalling in Fibulin-4 deficient SMCs compared to Fibulin-4+/+ SMCs. (e) Measurement of basal TGF-β 
activity (no stimulation with exogenous TGF-β ) by the CAGA-luciferase reporter show increased TGF-β 
activity in Fibulin-4R/R SMCs compared to Fibulin-4+/+ SMCs, which can be inhibited by the Tβ RI kinase 
inhibitor SB431542. (f) These data were confirmed by western blot analyses for pSMAD2 and pSMAD3. All 
data shown are representative for in total n = 3 independent experiments and all performed under serum 
starved conditions (*p < 0.05, **p < 0.01).
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Increased TGF-β1 and TGF-β2 levels in Fibulin-4 deficient SMCs. Since we observed increased 
basal TGF-β signalling in Fibulin-4 deficient SMCs, we analysed whether this was due to increased TGF-β 
levels. Subconfluent Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs were serum-starved and conditioned 
medium was collected for 4 consecutive days to determine TGF-β 1, − β 2 and − β 3 levels. TGF-β 3 
levels were very low and did not differ between the different genotypes (data not shown). Although 
Tgf-β1 mRNA levels in SMCs did not differ between the genotypes (Fig. 4a), TGF-β 1 levels in Fibulin-
4R/R SMCs conditioned medium were higher compared to Fibulin-4+/+ SMCs (Fig.  4b). Conditioned 
medium from Fibulin-4+/R SMCs showed intermediate TGF-β 1 levels. To analyse whether the increased 
TGF-β 1 levels were also observed in vivo, we prepared lysates from aortic arches of Fibulin-4+/+, Fibulin-
4+/R and Fibulin-4R/R mice and measured TGF-β 1 levels. These data revealed a similar gradual increase in 
TGF-β 1 levels in aortic arch lysates of Fibulin-4+/R and Fibulin-4R/R mice (Fig. 4c).
Figure 4. Strong increase of TGF-β2 levels in Fibulin-4 deficient SMCs. (a) Fibulin-4+/R and Fibulin-4R/R 
SMCs show equal Tgf-β1 mRNA expression levels compared to Fibulin-4+/+ SMCs. (b) Increased TGF-β 1 
levels measured in conditioned medium (CM) from Fibulin-4R/R SMCs compared to Fibulin-4+/+ CM on 
day 1–4 after serum starvation. Fibulin-4+/R SMCs showed significant increased TGF-β 1 levels on day 2 
and 4 after serum starvation compared to Fibulin-4+/+ SMCs. Furthermore, on day 4 Fibulin-4R/R SMCs 
show significant increased TGF-β 1 levels compared to Fibulin-4+/R SMCs (n = 4 per day for each genotype). 
Two-way ANOVA analysis for genotype and between days p < 0.05. (c) Gradually increased TGF-β 1 is also 
observed in aortic arch lysates of Fibulin-4+/R (n = 6) and Fibulin-4R/R mice (n = 5) compared to Fibulin-4+/+ 
aortas (n = 5). This increase is significant in Fibulin-4R/R aortic arch lysates compared to Fibulin-4+/+ aortic 
arch lysates. (d) Fibulin-4+/R and Fibulin-4R/R SMCs show gradual increased Tgf-β2 mRNA expression 
levels compared to Fibulin-4+/+ SMCs. (e) Measurement of TGF-β 2 revealed markedly increased levels in 
CM of Fibulin-4+/R and Fibulin-4R/R SMCs, while TGF-β 2 was undetectable in CM of Fibulin-4+/+ SMCs 
(experiments were performed in at least 3 independent experiments). Two-way ANOVA analysis for 
genotype and between days p < 0.05. (f) Measurements in aortic arch lysates display significantly increased 
TGF-β 2 in Fibulin-4R/R aortas compared to Fibulin-4+/R and Fibulin-4+/+ aortas (*p < 0.05, **p < 0.01).
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Next, we analysed TGF-β 2 expression in the SMCs. Fibulin-4+/R and Fibulin-4R/R SMCs showed 
> 5-fold increased Tgf-β2 mRNA expression levels (Fig.  4d). ELISA analysis on conditioned medium 
from Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs revealed strongly increased TGF-β 2 levels in 
medium from Fibulin-4+/R and Fibulin-4R/R SMCs compared to Fibulin-4+/+ SMCs, in which TGF-β 2 
was undetectable (Fig. 4e). TGF-β 2 levels were already significantly higher in conditioned medium from 
Fibulin-4+/R SMCs. Increased TGF-β 2 levels were also detectable in Fibulin-4R/R aortic arch lysates, when 
compared to aortic arch lysates from Fibulin-4+/+ and Fibulin-4+/R mice (Fig.  4f). Given the increased 
TGF-β levels in SMCs and aortic tissue derived from Fibulin-4 deficient mice, we determined TGF-β 1 
and TGF-β 2 levels in plasma samples from these mice. TGF-β 1 levels were not significantly differ-
ent among plasma from Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R mice (Fig.  5a). In contrast, plasma 
TGF-β 2 levels were very low in wild type mice and could be detected in 2 out of 15 Fibulin-4+/+ mice 
and 2 out of 19 Fibulin-4+/R mice (Fig. 5b). TGF-β 2 levels could be detected in plasma from 12 out of 
24 Fibulin-4R/R mice with significantly higher concentrations compared to Fibulin-4+/+ and Fibulin-4+/R 
mice. These data show that specifically TGF-β 2 levels in aortic tissue and plasma of Fibulin-4 deficient 
mice are strongly increased.
Losartan treatment rescues lethality and lowers plasma TGF-β2 levels in Fibulin-4R/R 
mice. Next, adult mice were treated with Losartan, an angiotensin-II type-I receptor blocker, which 
prevents aortic root enlargement and reduces circulating TGF-β 1 in a Marfan mouse model30. Compared 
to the increased secretion of TGF-β 2 in placebo treated Fibulin-4R/R mice we observed, TGF-β 2 lev-
els were not detectable in the 10 losartan treated Fibulin-4R/R mice. Consistent with previous studies31, 
Losartan treatment of wild type, Fibulin-4+/R and Fibulin-4R/R mice showed improved survival rates 
of Losartan treated Fibulin-4R/R mice until at least the age of 160 days compared to placebo treated 
Fibulin-4R/R mice, which maximally survive until the age of 100 days (Fig. 5c). All losartan and placebo 
treated wild type and Fibulin-4+/R mice survived at least until the duration of the experiment (data not 
shown). Despite improved survival, 160 days old Losartan treated Fibulin-4R/R mice developed signifi-
cantly enlarged aortic diameters compared to losartan treated wild type mice (Fig. 5d), and a thickened 
and degenerated aortic wall architecture as evidenced by fragmentation of its elastin layers (Fig.  5e). 
Previously, we showed a reduced SMA staining in the aortic wall of 100 days old Fibulin-4 deficient 
mice, indicative for SMC loss31. This SMC loss is not ameliorated by losartan treatment of Fibulin-4R/R 
mice (Fig.  5e). Both placebo and Losartan treated Fibulin-4+/R mice showed an increase in aortic wall 
thickness and minor elastin breaks compared to wild type mice, which was also previously observed in 
non-treated Fibulin-4+/R mice12. These results show that lethality and increased plasma TGF-β 2 levels 
in Fibulin-4R/R mice can be reduced by losartan treatment, showing a causal relation between increased 
TGF-β signalling and lethality in aneurysmal Fibulin-4 mice.
Discussion
In this study we show that TGF-β signalling is gradually enhanced in Fibulin-4 deficient SMCs in a 
Fibulin-4 dose-dependent manner and influences proliferation of these cells. The increased TGF-β sig-
nalling is consistent with increased TGF-β 1 levels, and especially with increased TGF-β 2 levels, detected 
in plasma from Fibulin-4 deficient mice.
Previous analyses on aortas from Fibulin-4 deficient mice showed increased TGF-β signalling asso-
ciated with aneurysm formation by gene expression analysis and increased nuclear pSMAD2 staining in 
the SMCs of these aortas12. Isolation of aortic SMCs from these mice provided the opportunity to assess 
TGF-β signalling in vitro. Fibulin-4R/R SMCs have a reduced proliferation rate compared to Fibulin-4+/R 
and wild type SMCs, which is reversed by TGF-β inhibition. Reduced proliferation only takes place 
after a prolonged incubation time, which is most probably caused by the requirement of certain levels of 
TGF-β before it affects the proliferation rates of the SMCs. However, in the aortic wall local active TGF-β 
concentrations can be much higher, due to local activation of the ECM bound TGF-β . In our previous 
studies we found a hyperproliferation of SMCs as well as a decreased SMC content in the aortic wall 
of Fibulin-4 deficient mice12,31. The hyperproliferation of SMCs was specifically found in the adventitial 
layers of the aortic wall of newborns. Tsai et al. showed that TGF-β can transform from an inhibitor to 
a stimulant of SMC proliferation in the context of elevated SMAD332. We observed a gradual increase 
in TGF-β signalling in Fibulin-4 deficient SMCs, which could be reverted by inhibition of TGF-β . These 
data indicate that the proliferation of Fibulin-4 deficient SMCs is reduced due to increased TGF-β sig-
nalling, thereby potentially contributing to aortic aneurysm formation.
ELISA analyses point to increased TGF-β 1 levels in Fibulin-4 deficient SMCs and strongly increased 
TGF-β 2 levels, also detected in plasma of Fibulin-4R/R mice. The three TGF-β isoforms are involved in 
both overlapping and divergent roles. While Tgf-β1 null mice develop an autoimmune-like inflamma-
tory disease33 and Tgf-β3 knockout mice show abnormal lung development and cleft palate34, Tgf-β2 
knockout mice have multiple developmental defects, including cardiovascular, pulmonary, skeletal, 
ocular, inner ear and urogenital manifestations35. Tgf-β2 heterozygous mutations in patients result in 
a different phenotype compared to Tgf-β2 knock-out mice15. TGF-β 2 haplo-insufficiency predisposes 
for adult-onset vascular disease, including aortic tortuosity and dilation, cerebrovascular disease and 
mitral valve disease, which overlaps with the phenotype of Fibulin-4 deficient patients. The phenotype 
of the TGF-β 2 deficient patients also shows overlap with other TGF-β signalopathies including Marfan 
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Figure 5. Increased levels of TGF-β2 are detectable in plasma from 100 days old Fibulin-4R/R mice, 
which reduces on Losartan treatment. (a) TGF-β 1 measurements in plasma samples showed no difference 
between placebo treated Fibulin-4+/+ (n = 9), Fibulin-4+/R (n = 8) and Fibulin-4R/R mice (n = 10). (b) TGF-β 2 
was detectable in plasma of 12 out of 24 placebo treated Fibulin-4R/R mice compared to only 2 out of 15 in 
placebo treated Fibulin-4+/+ mice and 2 out of 19 in Fibulin-4+/R mice. TGF-β 2 levels are significantly higher 
in Fibulin-4R/R mice compared to placebo treated Fibulin-4+/+ and Fibulin-4+/R mice. Losartan treatment of 
Fibulin-4R/R mice seemed to reduce the TGF-β 2 levels (0 out of 9) as compared to placebo treated Fibulin-
4R/R mice. The red line indicates the detection of the ELISA (Chi-square p < 0.001). (c) Kaplan-Meier 
survival curve shows an increased survival of Losartan treated Fibulin-4R/R mice compared to placebo treated 
Fibulin-4R/R mice. (d) Aortic diameter of 160 days old placebo and losartan treated Fibulin-4+/+, Fibulin-4+/R 
mice and Losartan treated Fibulin-4R/R mice. Losartan treated Fibulin-4R/R mice have significantly enlarged 
aortic diameters compared to wild type mice, while there are no differences between placebo and Losartan 
Fibulin-4+/R mice and wild type mice. (e) HE, elastin and α SMA staining of ascending thoracic aortas. 
Placebo and losartan treated Fibulin-4+/R mice (160 days old) show an increase in aortic wall thickness and 
some elastin breaks compared to Fibulin-4+/+ mice. Losartan treated Fibulin-4R/R mice show despite of their 
survival disrupted aortic wall architecture. In addition, despite losartan treatment there is loss of smooth 
muscle cell content in the media of Fibulin-4R/R mice. (*p < 0.05, **p < 0.01).
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syndrome, Loeys-Dietz syndrome, the aneurysm-osteoarthritis syndrome and similarly present with a 
paradoxical, probably compensatory, local increase in TGF-β 1 and TGF-β 2. Furthermore, increased 
Tgf-β2 expression has been detected in patients with the Loeys-Dietz syndrome36. The fact that TGF-β 2 
haplo-insufficiency results in a cardiovascular phenotype and local increased TGF-β 2, stresses the poten-
tial importance of TGF-β 2 in the vasculopathy. For various TGF-β superfamily members it is known 
that their effects are very concentration dependent37,38. Very high or very low levels of these cytokines 
can have similar or opposite effects on cells. In addition, crucial in the regulation of TGF-β activity is 
its activation from the latent ECM-bound complexes. This might explain the, at first sight, contradictory 
findings. This also suggests that increased TGF-β 2 expression is part of a common pathophysiologic 
process involved in aortic aneurysm formation in these syndromes. Whether it is a direct or indirect 
consequence of Fibulin-4 deficiency has to be determined in further studies.
We observed that specifically the TGF-β 2 isoform is elevated and detected at higher levels in the 
conditioned medium from these cells and in vivo in aortic lysates and blood. TGF-β 2 differs in its 
receptor binding properties from TGF-β 1 and TGF-β 3. While TGF-β 1 and TGF-β 3 have a high affin-
ity for binding to Tβ RII, TGF-β 2 primarily binds to the transforming growth factor type-III receptor 
(Tβ RIII), also called betaglycan, after which it presents the ligand to the Tβ RI-Tβ RII signalling com-
plex39. Bee et al. showed a specific regulatory role for the TGF-β receptor-IIb (Tβ RIIb), an alternatively 
spliced variant of Tβ RII, in TGF-β 2 signal transduction. Tβ RIIb mutations result in TGF-β 2 dependent 
increased SMAD2 phosphorylation, which is involved in aortic aneurysm progression40. Human SMCs 
express Tβ RI, Tβ RII and Tβ RIII, while in SMCs derived from atherosclerotic lesions Tβ RII expression 
is decreased41. This indicates that alterations in TGF-β receptor expression probably contribute to the 
regulation of the TGF-β pathway. As our data point to markedly increased TGF-β 2 levels in Fibulin-4 
deficient SMCs, analyses on TGF-β receptors on these SMCs might further clarify the process of TGF-β 
regulation and determine its role in the pathogenesis of Fibulin-4 associated aortic aneurysms.
Increased TGF-β levels or TGF-β signalling is associated with multiple diseases. Enhanced TGF-β 
signalling is known to mediate a pathologic increase in ECM secretion and deposition and is caus-
ative for fibrosis in multiple disorders throughout the body42. Overexpression of TGF-β 2 is likely to 
induce trabecular meshwork ECM deposition43 and increased ECM deposition is also observed in aortic 
aneurysm formation. TGF-β 2 is also frequently overexpressed in malignant cancers, where it induces 
immunosuppression and stimulates metastasis formation44. TGF-β 2 expression can be targeted with anti-
sense oligonucleotides, which are currently under investigation in clinical trials45. As inhibition with pan 
TGF-β neutralizing antibodies is likely to induce side effects, aortic aneurysms associated with increased 
TGF-β 2 might benefit from a TGF-β 2 specific intervention decreasing systemic side effects by targeting 
the other isoforms. In Marfan patients, mouse models for Loeys-Dietz syndrome and transverse aortic 
constriction (TAC), losartan treatment prevents aortic aneurysm formation accompanied by reduced 
TGF-β 1 levels in patients with Marfan syndrome, and reduced TGF-β 1 and TGF-β 2 levels in Loeys-Dietz 
syndrome and TAC mice30,36,46,47. Our data indicate that losartan could also serve as an important ther-
apeutic agent. The exact mechanism how losartan treatment leads to reduced TGF-β signalling needs to 
be determined.
Fibulin-4 binds LTBP-1 with high affinity and therefore an important role for Fibulin-4 in the associ-
ation of LTBP-1 with microfibrils is predicted. The large latent complex (LLC), which is formed by LTBP 
and LAP-bound TGF-β , is linked to microfibrils through binding of LTBP-1 to Fibrillin-1. Therefore, 
Fibulin-4 might be additionally involved in sequestering of the LLC through LTBP-1 binding48. We spec-
ulate that reduced Fibulin-4 levels lead to defective sequestering to the ECM and thereby increased free 
TGF-β 1 and TGF-β 2. In conclusion, these data show that SMC derived TGF-β 2 is associated with aortic 
aneurysm formation and levels decrease upon losartan treatment, which improves survival of Fibulin-4 
deficient mice. Specific intervention on TGF-β 2 could provide more information on its role in the patho-
genesis of aortic aneurysm formation. In vitro analyses on isolated SMCs provide the opportunity to 
determine the molecular link between Fibulin-4 and TGF-β pathway regulation, and to further unravel 
its role in aortic aneurysm formation.
Material and Methods
Animals. Mice containing the Fibulin-4R allele were generated as previously described12. All mice used 
were bred in a C57BI/6J background and were kept in individually ventilated cages to keep animals con-
sistently micro-flora and disease free. To avoid stress-related vascular injury, mice were earmarked and 
genotyped 4 weeks after birth. Animals were housed at the Animal Resource Centre (Erasmus University 
Medical Centre), which operates in compliance with the “Animal Welfare Act” of the Dutch government, 
using the “Guide for the Care and Use of Laboratory Animals” as its standard. As required by Dutch 
law, formal permission to generate and use genetically modified animals was obtained from the respon-
sible local and national authorities. All animal studies were approved by an independent Animal Ethical 
Committee (Dutch equivalent of the IACUC).
Treatment of mice. Fibulin-4+/+ and Fibulin-4R/R mice received 0.6 gram/liter losartan (Sigma, 
Zwijndrecht, the Netherlands) or placebo in their drinking water as previously described30,31. Adult 
Fibulin-4R/R mice and their wild type littermates were treated during 10 weeks or 18 weeks, starting at the 
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age of 5 weeks. Blood samples from placebo or losartan treated Fibulin-4+/+ and Fibulin-4R/R mice were 
obtained by cardiac puncture and collected in lithium heparin vials (Sarstedt, Numbrecht, Germany).
Isolation of SMCs and cell culture. Vascular SMCs were isolated from the luminal side of the 
aortic arch from Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R male mice. The tissue was washed with 
phosphate-buffered saline (PBS), cut into 5-mm pieces with the luminal side on 0.1% gelatine coated cell 
culture dishes and incubated. After 7–10 days, smooth muscle-like cell outgrowth was observed. SMCs 
were maintained in DMEM (Lonza, Leusden, the Netherlands), supplemented with 10% etal calf serum 
(HyClone, Thermo Scientific, Breda, the Netherlands), 100 U/ml penicillin and 100 μ g/ml streptomycin 
(Sigma-Aldrich, Zwijndrecht, the Netherlands). Cells were used at passage 5–11.
Immuno-fluorescent and –histochemical stainings. Subconfluent SMCs, Human Umbilical Vein 
Endothelial Cells (HUVECs), isolated as described before49, and Mouse Embryonic Fibroblasts (MEFs), 
isolated from 8 day old C57/Bl6 mouse embryos, were grown on coverslips and fixed in 1% paraformal-
dehyde. Cells were permeabilised with 0.1% Triton/PBS and blocked with PBS containing 1.5% bovine 
serum albumin/0.15% glycine (Sigma). Next, coverslips were incubated overnight at 4 °C with the pri-
mary antibodies; mouse anti-smooth muscle actin 1:1500 (Progen, Heidelberg, Germany), rabbit pol-
yclonal anti-SM22 alpha antibody 1:400 (Abcam, Cambridge, UK), mouse monoclonal anti-smooth 
muscle myosin heavy chain II 1G12 1:500 (Abcam, Cambridge, UK), rabbit anti-CD31 1:800 (Santa Cruz 
Biotechnologies, Santa Cruz, USA) and rabbit anti-Fibroblast Specific Protein1 (FSP-1)/S100A4 1:1600 
(Millipore, MA, USA). The next day cells were incubated with secondary antibodies anti-mouse alex-
afluor 488 1:1000 (Molecular Probes, Eugene, Oregon) for SMA and MHC II and anti-rabbit alexafluor 
594 1:1000 (Molecular Probes, Eugene, Oregon) for SM22, CD31 and FSP-1, and mounted with DAPI. 
Slides were analysed with the LEICA DMRBE Aristoplan Microscope equipped with the Hamamatsu 
ORCA-ER Camera. Pictures were taken at 25x magnification. To analyse in vivo SMC content and pro-
liferation 4 μ m sections of paraffin embedded aortas were stained with haematoxylin and eosin, elastin 
(Verhoeff-van Gieson), and α -smooth muscle actin as described before31. BrdU staining was performed 
according to the manufacturers’ protocol (Roche, Basel, Switzerland).
Proliferation assay. Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs were seeded in triplicate 
in 6 cm dishes (5000 cells/well) and allowed to attach overnight. Next, cells were treated with TGF-β 
neutralizing antibodies (kindly provided by Dr. E. de Heer, Leiden University Medical Centre, Dept. 
of Pathology26,27) and counted every day using a Burker cell counting chamber. Medium was replaced 
every other day. The MTS proliferation assay was performed according to the manufacturer’s instructions 
(Promega, Madison, USA). In short, SMCs were seeded in 96-well plates (1500 cells/well) and allowed to 
attach overnight. At day-1, -2 and -3 medium was changed to 100 μ l complete DMEM + 20 μ l MTS sub-
strate and the metabolic activity of the cells was analysed by absorbance change at 490 nm after 2 hours.
TGF-β response assay. TGF-β response in SMCs was determined using (CAGA)12− MLP− Luciferase 
promoter reporter construct28. This construct contains 12 palindromic repeats of the SMAD3/4 binding 
element derived from the PAI-1 promoter and was shown to be highly specific and sensitive to TGF-β . 
The assay was performed as described previously29. In short SMCs were seeded in 1% gelatin coated 
24-well plates and allowed to attach overnight. Subconfluent cells were transfected using Lipofectamin 
2000 (Invitrogen, Carlsbad, California, USA) according to the manufacturer’s protocol. A β -galactosidase 
plasmid was co-transfected to correct for transfection efficiency. After 6 hours, medium was changed to 
DMEM containing 10% FCS and the cells were incubated for 24 hours. Next, cells were serum-starved 
overnight and stimulated with 5 ng/ml TGF-β 3 (kindly provided by Kenneth K. Iwata, OSI, Inc., New 
York, USA) in the presence or absence of 10 uM SB431542 (Tocris/R&D systems, Abington, UK) for 
6 hours. After stimulation the cells were washed, lysed and luciferase activity was determined accord-
ing to the manufacturer’s protocol (Promega). β -Galactosidase activity in the lysates was deter-
mined using β -gal substrate (0.2 M H2PO4, 2 mM MgCl2, 4 mM ortho-nitrophenyl-phosphate, 0.25% 
β -mercaptoethanol) and measuring absorbance change at 405 nm. The luciferase count was corrected 
for β -galactosidase activity. The relative increase in luciferase activity was calculated versus controls. All 
experiments were performed at least three times in triplicate. To determine the transfection efficiency of 
Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R SMCs they were transfected with a GFP plasmid as described 
above, trypsinised and fixed with 1% PFA. Subsequently, SMCs were analysed with flow cytometry for 
the percentage of GFP transfected SMCs compared to the total amount of SMCs.
Western blot analysis. Western blot analysis was performed as described before50. In short, equal 
amounts of protein (DC protein assay, Bio-Rad Laboratories, Hercules, CA, USA) were separated on 
10% SDS− polyacrylamide gel electrophoresis under reducing conditions. Proteins were transferred 
to nitrocellulose membranes (Whattman, Dassel, Germany) and blocked with 5% milk powder in 
Tris-HCl buffered saline containing 0.05% Tween-20 (Merck, Darmstadt, Germany). After washing, 
blots were overnight incubated with rabbit anti-pSMAD2 (Cell signaling Technologies, USA) and rabbit 
anti-pSMAD3 (kindly provided by Dr. E. Leof, Mayo Clinic, Rochester, MN, USA) followed by horserad-
ish peroxidase-conjugated secondary antibodies (all GE Healthcare, Waukesha, WI, USA). Detection was 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 5:16872 | DOI: 10.1038/srep16872
performed by chemoluminescence according to the manufacturer’s protocol (Pierce, Rockford, IL, USA). 
Afterwards, blots were stripped and reprobed with mouse anti-β -actin antibodies as a loading control.
RNA isolation and real-time PCR. RNA was isolated using RNeasy Mini Kit according to the manu-
facturer’s instructions (Qiagen, Hilden, Germany). RNA concentration and purity was determined spec-
trometrically. Complementary DNA synthesis was performed using random primers. cDNA samples 
were subjected to 40 cycles real-time PCR analysis using maxima SYBR Green qPCR Master Mix 2× 
(Fermentas, Vilnius, Lithuania) and primers shown in Table 1. Reactions were performed in triplicates 
for each sample. Product specificity was determined by melting curve analysis and gel electrophoresis. 
The average Ct values of the triple reactions were calculated for each gene and all values were normalized 
for cDNA content by Hprt expression. The levels of fold-change for each gene were calculated relative to 
the gene expression levels in baseline wild type SMCs. RNA isolated from HUVECs and fibroblasts were 
used as controls for the genes analysed.
TGF-β ELISAs. SMC conditioned medium was prepared by seeding the cells and growing them to 
subconfluence. Medium was changed to serum-free DMEM, containing antibiotics as described above, 
and incubated for 4 days. Samples were collected every day and frozen at − 20 until analysis. Lysates 
were prepared from aortic arches of 14–15 week old Fibulin-4+/+, Fibulin-4+/R and Fibulin-4R/R mice 
and protein amounts were determined (Pierce BCA protein assay kit, Thermo Scientific). Total TGF-β 1, 
TGF-β 2, and TGF-β 3 levels in CM samples, aortic arch lysates and plasma samples were determined by 
commercially available duo-sets (R&D Systems) using transient acidification as described before51.
Statistical analysis. Data are presented as mean ± SEM. The non-parametric Mann-Whitney U-test 
and unpaired student’s t-test were performed to analyse the specific sample groups for significant differ-
ences. The two-way ANOVA test was used to test significant differences between independent variables. 
A p-value of < 0.05 was considered to indicate a significant difference between groups. All analyses were 
performed using IBM SPSS Statistics version 20.0 and 22.0 (SPSS Inc., Chicago, IL, USA).
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